RxDoctor Payments Data

Rebel Smith

Family · Sallisaw, OKNPI 1659373223

Payments from drug & device makers

$1,102in general payments, 2019–2025

Across 38 payments — averaging $29.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$342
  • Lilly USA, LLC$200
  • Novo Nordisk$182
  • Bayer$142
  • Axsome Therapeutics, Inc.$115
  • AstraZeneca$42
  • plus $79 from 3 others

What the payments were for

  • Food & beverage$1,102100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,102 in reported general payments places this provider in the 70th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$831
Medicare patients
13
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide30$50,174
JardianceEmpagliflozin32$32,722
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$27,180
OzempicSemaglutide15$22,523
EliquisApixaban27$21,143
Spiriva HandihalerTiotropium Bromide15$13,495
FarxigaDapagliflozin Propanediol20$12,069
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$3,703
Albuterol Sulfate HfaAlbuterol Sulfate87$1,825
Atorvastatin Calcium147$1,646
Gabapentin156$1,610
Duloxetine Hcl56$1,554
Lisinopril162$1,454
Omeprazole82$1,145
Tamsulosin Hcl61$966

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$200$50,17430 claims
Novo NordiskOzempic$182$22,52315 claims
PfizerEliquis$342$21,14327 claims
AstraZenecaFarxiga$42$12,06920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,026 family providers in Oklahoma.

Other family in Sallisaw

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →